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Synthetic high- and low-molecular-mass trial peptides were phosphorylated in vitro by cyclic AMP-depen- 
dent protein kinase and [3zp]ATP. From a series of atrial peptide analogs, it was deduced that the amino 
acid sequence, Argl°l-Ser TM of atriopeptin was required for optimal phosphorylation. Phosphorylated 
AP(99-126) was less potent han the parent atriopeptin i  vasorelaxant activity and receptor-binding pro- 
perties. These results indicate that the presence of a phosphate group at the N-terminus of AP(9%126) de- 
creases the interaction of the peptide with its receptor and, as a consequence, decreases bioactivity. These 
observations are in contrast to those of Rittenhouse et al. [(1986) J. Biol. Chem. 261, 7607 7610] who re- 
ported that phosphorylation f AP(101 126) enhanced the stimulation of Na/K/CI cotransport in cultured 
vascular smooth muscle cells. 
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1. INTRODUCTION 
The vasorelaxant, natriuretic and diuretic pro- 
perties of atrial natriuretic peptide enable it to play 
an important role in the regulation of blood 
pressure and fluid volume [1,2]. The circulating 
form of the peptide, AP(99-126), consists of 28 
amino acids, and is derived from the carboxyl- 
terminus of a 126-amino-acid prohormone, 
AP(1-126), stored in specific granules in the heart 
[3]. A disulfide bridge links two cysteine residues 
at positions 105 and 121 of the peptide to form a 
ring structure which is required for biological ac- 
tivity [4-61. 
Peptides and proteins containing the sequence, 
Arg-Arg-X-Ser(P), often serve as phospho- 
rylatable substrates for cyclic AMP-dependent 
protein kinase [7]. We and others [8,9] have 
observed that this recognition sequence is also 
present in AP(99-126): 
99 
d' 
Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg- 
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Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu- 
I 
Gly-Cys-Asn-Ser-Phe-Arg-Tyr 
126 
Based on this observation, we wished to deter- 
mine the sequence specificity for phosphorylation 
of various atrial peptide analogs by cyclic AMP- 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/87/$3.50 © 1987 Federation of European Biochemical Societies 325 
Volume 224, number 2 FEBS LETTERS November 1987 
dependent protein kinase, and the biological 
properties of phosphorylated AP(99-126). 
2. MATERIALS AND METHODS 
2.1. Materials 
The catalytic subunit of cyclic AMP-dependent 
protein kinase was obtained from Sigma. 
[7-32p]ATP was purchased from New England 
Nuclear. Adenosine 5'-triphosphate (ATP) and 
adenosine 5'-O-(3-thiotriphosphate) were obtain- 
ed from Boehringer Mannheim. Rat atriopep- 
tin(99-126) was purchased from Peninsula 
Laboratories. Electrophoresis reagents and 
molecular mass standards were from Bio-Rad. 
2.2. Peptide synthesis 
Atrial peptide analogs were synthesized by the 
Merrifield method using PAM resin [10] for pep- 
tide acids, and mBHA resin [11] for peptide 
amides. Peptides were cleaved from the resins with 
liquid HF/anisole (9: 1, v/v) for 60 min at 0°C. 
Free peptides were purified by reverse-phase 
HPLC on a Waters/~Bondapak C~8 column using 
a linear gradient of 15-40°70 acetonitrile in water 
containing 0.05°7o trifluoroacetic acid at a flow 
rate of 1 ml/min for 25 min. Disulfide bond for- 
mation was accomplished by air oxidation in 
0.1 M ammonium bicarbonate (pH 7) at a peptide 
concentration of 0.1 mg/ml. The cyclized product 
was purified on a/~Bondapak column, and the in- 
tegrity was verified by amino acid and gas-phase 
sequence analyses. 
2.3. Preparation of atrial peptide prohormone 
The atrial peptide prohormone used in the 
[32p]phosphate-labelling studies consisted of 
amino acid residues 24-152 of the rat preprohor- 
mone coding sequence [12]. The gene was express- 
ed in E. coli (Olins, P.O. et al., in preparation). 
The prohormone was extracted from the cells using 
1 M acetic acid, and purified by reverse-phase and 
ion-exchange chromatography [13]. 
Tris-HC1, pH 7.4, 10 mM MgC12, 0.2 mM 
[7-32p]ATP, and the catalytic subunit of cyclic 
AMP-dependent protein kinase (15 U). The reac- 
tions were terminated by the addition of EDTA to 
a final concentration of 10 mM. The samples were 
subjected to SDS-polyacrylamide gel elec- 
trophoresis [14] on a 15°70 polyacrylamide g l con- 
taining 0.1°70 SDS. The gel was stained, dried and 
subjected to autoradiography in order to detect 
32p-labelled peptides. 
2.5. Preparation of phosphorylated and thio- 
phosphorylated AP(99-126) 
Phosphorylated AP(99-126) was prepared 
essentially by the method of Rittenhouse t al. [8]. 
Briefly, AP(99-126) (750/~g/0.1 ml) was in- 
cubated for 60 min at 30°C in the presence of 
15 mM MgC12, 62.5 mM Mes, pH 6.5, 0.24 mM 
EGTA, 1.5 mM ATP and the catalytic subunit of 
cyclic AMP-dependent protein kinase (3000 U). 
The reaction was terminated by the addition of 
EDTA to a final concentration of 20 mM. 
Thiophosphorylated AP(99-126) was similarly 
prepared except adenosine 5'-O-(3-thiotriphos- 
phate) was substituted for ATP in the incubation. 
Phosphorylated and thiophosphorylated 
AP(99-126) were purified by reverse-phase 
HPLC. The reaction mixtures were injected onto a 
Vydac C18 column (10 mm i.d. x 25 cm; 5/~m/ 
300 nm) equilibrated with water containing 0.05O7o 
trifluoroacetic acid. A linear gradient of 0-23°7o 
acetonitrile containing 0.05°70 trifluoroacetic acid 
was developed for 17 min at a flow rate of 2 ml/ 
min. Phosphorylated and thiophosphorylated 
atrial peptides eluted during isocratic onditions of 
23°7o acetonitrile. Both the gradient and flow rate 
were maintained by a Waters HPLC system con- 
sisting of two model 510 pumps connected to an 
automated gradient controller. Column effluent 
was monitored at 220 nm by a Waters model 481 
spectrophotometer. Column fractions containing 
the phosphorylated or thiophosphorylated 
AP(99-126) were pooled, lyophilized and stored at 
-70°C until use. 
2.4. 32p labelling of high- and low-molecular-mass 
atrial peptides 
Low- (0.6/zg) and high- (3/~g) molecular-mass 
atrial peptides were incubated at 30°C for 30 min 
in 0.03 ml reaction mixtures containing 50 mM 
2.6. AP receptor-binding and bioactivity assays 
Receptor-binding properties of atrial peptides 
were studied by measuring the displacement of 
lzsI-labelled AP(99-126) from the rabbit lung 
membrane receptor [15]. Atrial peptides were 
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assayed for vasorelaxant activity using norepine- 
phrine-contracted rabbit thoracic aortic strips [2]. 
3. RESULTS AND DISCUSSION 
3.1. Sequence requirements for atrial peptide 
phosphorylation 
A series of atrial peptide analogs (table 1) were 
incubated with cyclic AMP-dependent protein 
kinase in the presence of [32p]ATP. The incuba- 
tion mixtures were analyzed by SDS-polyacryl- 
amide gel electrophoresis and autoradiography to 
detect 32p-labelled peptides (fig. 1). [32p]Phosphate 
was incorporated into the circulating form of 
atriopeptin, AP(99-126), which contains the 
protein kinase recognition sequence, Arg ~°l- 
Arg~°2-Serl°3-Serl°4. In contrast, AP(103-126), 
which lacks the two arginines of the recognition 
sequence, was not phosphorylated. Interestingly, 
AP(102-126) which retains only a portion of the 
protein kinase recognition sequence, Argl°Z-Serl°3- 
Ser TM, showed low levels of [32p]phosphate incor- 
poration. Other analogs of atrial peptides in which 
the recognition sequence was disrupted by deletion 
or substitution for other amino acids were not 
phosphorylated. These results indicate that the 
sequence Argl°l-Argl°Z-Serl°3-Serl°4 is required 
for the optimal phosphorylation f atrial peptides, 
and the results are consistent with Ser 1°4 being the 
site of phosphorylation [8]. 
An analog of the atrial peptide prohormone was 
also phosphorylated by cyclic AMP-dependent 
protein kinase, as shown in fig.1. Recently, Bloch 
et al. [9] have reported that a similar prohormone 
analog, AP(2-126), was phosphorylated, 
presumably at the Ser 1°4 position, by the same en- 
zyme in vitro. In addition, they studied the secre- 
tion of proatrial natriuretic factor (proANF) from 
cultured rat cardiocytes, and found that approx. 
35°7o of the secreted proANF was phosphorylated. 
However, incorporation of phosphate was local- 
ized to the amino-terminal portion of the prohor- 
mone, and not in residues 99-126, the amino acid 
sequence of the mature peptide. It is not known 
whether cyclic AMP-dependent protein kinase or 
an alternative protein kinase was responsible for 
the phosphorylation. Moreover, it is still unclear 
whether phosphorylation of proANF plays a role 
in its storage or secretion from atrial cardiocytes. 
3.2. Biological properties of phosphorylated and 
thiophosphorylated atrial peptides 
To determine the effect of phosphorylation on 
the biological activities of atrial peptides, 
AP(99-126) was phosphorylated by incubation 
with cyclic AMP-dependent protein kinase and 
ATP, and purified by reverse-phase HPLC. Fig.2 
shows HPLC profiles of the crude and purified 
phosphorylated AP(99-126). Phosphorylated 
AP(99-126) competed with 125I-labelled AP- 
(99-126) for binding to rabbit lung atrial peptide 
binding sites (fig.3). The relative potency for 
phosphorylated AP(99-126) binding to the lung 
receptors was 0.28 vs the parent peptide. 
Phosphorylated AP(99-126) had the ability to 
relax norepinephrine-contracted rabbit aorta 
strips, and the relative potency vs AP(99-126) was 
determined to be 0.26 which correlated well with 
the receptor-binding data. 
We considered the possibility that the phosphate 
group on AP(99-126) might be susceptible to 
phosphatase digestion during assay, and that this 
Table 1 
N-terminal amino acid sequences of the low-molecular-mass atrial 
peptide analogs used in the phosphorylation studies 
Analog Sequence 
AP(99-126) 
SI°1,LI°2,R 1°3'1°4 AP(101-125)-NH2 
AP(102-126) 
R l°3 AP(103-125)-NH2 
R 1°3.1°4 AP(103-126) 
AP(103-126) 
99 102 105 
S -L -R-R-S -S -C -F -G ... 
S -L -R-R-C -F -G ... 
R-S -S -C -F -G ... 
R -S -C -F -G ... 
R-R-C -F -G ... 
S -S -C-F -G ... 
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Fig.l. Incorporation of [32p]phosphate into low- and 
high-molecular-mass atrial peptide analogs. Atrial 
peptides were incubated with [32p]ATP and cyclic AMP- 
dependent protein kinase as described in section 2 and 
the incubation mixtures were resolved by SDS- 
polyacrylamide g l electrophoresis. An autoradiograph 
of the stained and dried gel is shown, where the peptide 
substrates are as follows - lanes: 1, no substrate; 2, 
AP(99-126); 3, SI°ILI°ERI°3'I°4AP(101-125)-NH2; 
4, AP(102-126); 5, RI°3AP(103-125)-NH2; 6, 
Rl°3'l°4AP(103-126); 7, AP(103-126); 8, AP 
prohormone analog. 
might account for the residual bioactivity observed 
with the phosphorylated peptide. To rule this out, 
thiophosphorylated AP(99-126) was prepared us- 
ing adenosine 5'-O-(3-thiotriphosphate) and cyclic 
AMP-dependent protein kinase. Thiophospho- 
rylated compounds have been reported to be less 
susceptible to the action of phosphatases (review 
[16]). Fig.4 shows HPLC profiles of the crude and 
purified thiophosphorylated AP(99-126). Thio- 
phosphorylated AP(99-126) had receptor-binding 
(fig.5) and vasorelaxant properties imilar to the 
phosphorylated AP(99-126). The thiophosphory- 
lated peptide had relative potencies of 0.21 and 
0.26 for receptor-binding and vasorelaxant ac- 
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Retention Time (min) 
Fig.2. HPLC profiles of the crude and purified 
phosphorylated AP(99-126). (A) Sample of incubation 
mixture containing approx. 90/zg phosphorylated 
AP(99-126). (B) Sample (20/zg) of purified 
phosphorylated AP(99-126). Arrow denotes the 
absorbance peak of phosphorylated AP(99-126). 
tivities, respectively. The results are summarized in
table 2. 
Thus, the presence of a phosphate group in the 
N-terminal region of AP(99-126) appears to 
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Fig. 3. Competitive binding of phosphorylated 
AP(99-126) to rabbit lung membranes. The membranes 
were equilibrated with 90 pM ~25I-AP(99-126) and 
varying concentrations of unlabelled AP(99-126) ( i )  
and phosphorylated AP(99-126) (r~). Values of specific 
binding measured in the presence of unlabelled peptide 
(B) were expressed as a fraction of the specific binding 
measured in the absence of competitor (Bo). Data points 
represent the mean of two determinations. 
Fig.5. Competitive binding of thiophosphorylated 
AP(99-126) to rabbit lung membranes. The membranes 
were equilibrated with 90pM 125I-AP(99-126) and 
varying concentrations of unlabelled AP(99-126) (n) 
and thiophosphorylated AP(99-126) (n). Values of 
specific binding measured in the presence of unlabelled 
peptide (B) were expressed as a fraction of the specific 
binding measured in the absence of competitor (B0). 
Data points represent the mean of two determinations. 
decrease the interaction of the peptide with the 
atrial peptide receptor, and decreases biological ac- 
tivity. There are a number of possible explanations 
for this. Binding of the peptide to the atrial peptide 
receptor could be sterically hindered by the 
presence of a phosphate group. If the atrial peptide 
binding site contained a negatively charged amino 
acid residue, a phosphorylated atrial peptide might 
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Fig.4. HPLC profiles of the crude and purified thiophosphorylated AP(99-126). (A) Samples of incubation mixture 
containing approx. 90/zg thiophosphorylated AP(99-126). (B) Sample (20/zg) of purified thiophosphorylated 
AP(99-126). Arrow denotes the absorbance peak of thiophosphorylated AP(99-126). 
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Table 2 
Relative potencies of phosphorylated and 
thiophosphorylated AP(99-126) for receptor-binding 
affinity to rabbit lung membranes and vasorelaxant 
activity on norepinephrine-contracted rabbit aorta strips 
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Peptide Receptor Vasorelaxant 
binding activity 
AP(99-126) 1.00 1.00 
Phosphorylated 
AP(99-126) 0.28 0.26 
Thiophosphorylated 
AP(99-126) 0.21 0.26 
be repelled. Alternatively, if the positively charged 
arginine residues at the amino-terminus of the pep- 
tide were involved in binding to the atrial peptide 
receptor, a phosphate group might neutralize 
these. 
Although our results showed that phosphory- 
lated atrial peptides were approx. 4-fold less potent 
in receptor-binding and vasorelaxant properties, 
Rittenhouse t al. [8] have reported that phos- 
phorylated AP(101-126) and AP(99-126) were 
more effective than the corresponding dephospho 
forms in stimulating Na/K/C1 cotransport in 
cultured vascular smooth muscle cells. The reason 
for the discrepancy between these observations i
unclear, except hat different atrial peptide analogs 
were tested in different biological assays. Never- 
theless, phosphorylation of atrial peptides alters 
their receptor-binding and biological activities, 
and may therefore have an important role in 
modulating their action at the target tissue or 
perhaps in feedback control mechanisms. 
In summary, we have shown that Arg-Ser-Ser is 
the minimal sequence requirement for phosphory- 
lation of atrial peptides by cyclic AMP-dependent 
protein kinase. Phosphorylated atrial peptides 
have decreased biological activity due to the in- 
terference of the phosphate group with receptor- 
binding interactions. From these and other in vitro 
studies, evidence is accumulating that phos- 
phorylation may play a regulatory role in the 
storage, secretion and biological activity of these 
factors. It still remains to be determined whether 
atria, plasma or target tissues contain phosphory- 
lated atrial peptides. 
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